

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicants : Allen I. Bain et al.
Application No. : 10/674,684
Filed : September 29, 2003
For : ION CHANNEL MODULATING COMPOUNDS AND USES
THEREOF

Examiner : Rebecca L. Anderson
Art Unit : 1626
Docket No. : 480102.403C2
Date : June 29, 2005

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Form PTO-1449. Copies of the cited U.S. patents and published patent applications are not required and accordingly have not been provided. Copies of all other cited references are enclosed. As to any reference cited, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Second Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

07/01/2005 RFEKADU1 00000035 10674684


01 FC:1806

180.00 OP

Application No. 10/674,684

A fee of \$180 is submitted in accordance with 37 CFR 1.97(c). The Director is authorized to charge any other fees which may be required, or credit any overpayment to Deposit Account No. 19-1090.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC




Karl R. Hermanns
Registration No. 33,507

Enclosures:
Check
Form PTO-1449
Cited References (15)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

589359

FORM PTO-1449 (REV 12-30)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 480102.403C2		APPLICATION NO. 10/674,684	
				APPLICANT Allan I. Bain et al.			
				FILING DATE September 29, 2003		GROUP ART UNIT 1626	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AB						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AC	Beatch, G. et al., "Effect of a Novel Anti-tussive Compound CP1 Against Citric Acid Induced Cough in Guinea-Pigs" <i>Proc West Pharmacol Soc</i> , 2001.					
	AD	Doci, A. "Local Anesthetic Effects of Intradermal RSD921 In Healthy Subjects" in <i>Proceedings of the 100th Annual meeting of the American Society for Clinical Pharmacology and Therapeutics</i> , San Antonio, Texas, USA. March 18-20, 1999, 65(2): 177. February 1999. Abstract PIII-2.					
	AE	Franciosi, Luigi G. et al., "Phase III Clinical Trial of RSD921 as a Local Anaesthetic in Patients Undergoing Venous Cannulation For Elective Treatment" in <i>Proceedings of the 28th Annual ACCP Meet Abstract 32</i> , pp 977, February 2000.					
	AF	Hesketh, J., et al., "Safety of RSD1235 in a rabbit purkinje fiber model", in <i>Proceedings of the XIVth World Congress of Phar. Meeting Abstracts</i> : 22-12, 2002					
	AG	Kertesz, R. et al., "The Electrophysiological and Antiarrhythmic Actions of RSD Analogs of U50,488H in Rats" in <i>Proceedings of the West Pharmacol Soc.</i> 9 pages, 1994.					
	AH	Nattel, S. et al., "The Role of Channel Opening in Transient Outward Current Block By Quinidine, Flecainide, and 4-Aminopyridine in Human Atrial Myocytes" K Channels II: Regulation and Block, Abstract No. Tu-Pos403, 1994.					
	AI	Nattel, S. et al., "RSD1235: a novel antiarrhythmic agent with a unique electrophysiological profile that terminates AF in dogs" <i>Antiarrhythmic Agents</i> , pg 448, 2001.					
	AJ	Pugsley and Goldin, "Molecular analysis of the Na ⁺ channel blocking actions of the novel class I antiarrhythmic" <i>Br J Pharm</i> , 127:9-18, 1999.					
	AK	Pugsley, M.K. et al., "Electropharmacology of two new class 1 agents" <i>Heart and Stroke Annual Conference</i> , p. 12, 1995.					
	AL	Rich, T. C. et al. "Quinidine Block of the Human Cardiac hKv1.5 Channel in Inside-Out Patches" K Channels II: Regulation and Block, Abstract No. Tu-Pos404, 1999.					
EXAMINER				DATE CONSIDERED			
<p>* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).</p>							

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 480102.403C2	APPLICATION NO. 10/674,684
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT Allan I. Bain et al.	
		FILING DATE September 29, 2003	GROUP ART UNIT 1626

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	BH					
	BI					
	BJ					
	BK					
	BL					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	BM	Walker, Michael J.A. and Guppy, Leon J. "Targeting Ischemic Ventricular Arrhythmias" <i>Cardiac Drug Development Guide</i> , pp 175-201, 2002-2003.
	BN	Wat, J.Y.K. et al., "Effects of Arylbenzacetamides on Neuromuscular Preparation" <i>Proc West Pharmacol Soc</i> , 1994.
	BO	Wolf, et al. (1998) "Impact of Atrial Fibrillation on Mortality Stroke, and Medical Costs" <i>Arch Intern Med</i> 158: 229-234, 1999.
	BP	Wong, Judy et al., "Protein Binding Study of AA5, a New Antiarrhythmic Drug," Poster Conference, August 2000.
	BQ	Wong, L. et al., "Capillary Electrophoresis Assay to Assess In Vitro Metabolic Stability of Novel Compounds in Human Liver Microsomes," AAPS Poster, October 2001.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).